title: Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
abstract: Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients. We hypothetize that, owing to its anti-inflammatory/antiangiogenic/vascular growth maturation properties, thalidomide should be useful in the prophylaxis and therapy of HHT patients presenting with initial lung involvement.
authors: Pluridisciplinary HHT team, Ambroise Paré Hospital, 9, Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France. lacout.alexis@wanadoo.fr
authors: Alexis
authors: A
authors: Lacout
authors: Pierre Yves
authors: PY
authors: Marcy
authors: Mostafa
authors: M
authors: El Hajjam
authors: Pascal
authors: P
authors: Lacombe
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001164:Arteriovenous Fistula / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D011651:Pulmonary Artery / Q000002:abnormalities / Q000503:physiopathology; D011667:Pulmonary Veins / Q000002:abnormalities / Q000503:physiopathology; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide